NovoCure (NVCR) Total Debt Growth (3y) (2018 - 2026)
NovoCure (NVCR) Total Debt Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | 24.63% |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 4.89% |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 11.72% |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 0.11% |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | -0.47% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | -1.01% |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | -13.48% |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn | -29.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.84% |
| Mar 31, 2026 | -29.85% |
| Dec 31, 2025 | -29.87% |
| Sep 30, 2025 | -29.89% |
| Jun 30, 2025 | -44.27% |
| Mar 31, 2025 | -44.27% |
| Dec 31, 2024 | -44.27% |
| Sep 30, 2024 | -44.27% |
| Jun 30, 2024 | -44.28% |
| Mar 31, 2024 | 0.60% |
| Jun 30, 2023 | 55.96% |
| Mar 31, 2023 | 55.90% |
| Dec 31, 2022 | 55.84% |
| Sep 30, 2022 | 55.78% |
| Jun 30, 2022 | 55.71% |
| Mar 31, 2022 | 55.65% |
| Dec 31, 2021 | 55.59% |
| Sep 30, 2021 | 55.53% |
| Jun 30, 2021 | 55.46% |
| Mar 31, 2021 | 55.38% |